NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
XBIO
Xenetic Biosciences, Inc.
There isn't enough reported data to score XBIO yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
XBIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
XBIO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
XBIO PE Valuation
XBIO has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
XBIO Forward outlook
There aren't enough analyst estimates for XBIO to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over XBIO on earnings quality, reporting a profit while its opponent remains loss making.
XBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.51 |
| Q2 2026 | -$1.15 | +$0.85 |
| Q1 2026 | -$1.19 | +$1.19 |
| Q4 2025 | -$1.58 | +$0.99 |
| Q3 2025 | -$2.05 | +$0.57 |
| Q2 2025 | -$2.00 | +$1.03 |
| Q1 2025 | -$2.38 | +$0.51 |
| Q4 2024 | -$2.57 | +$0.14 |
XBIO is still losing money, but far less than before: $1.54 per share over the past year, against $17.00 at its worst in late 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over XBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over XBIO on profitability, with a higher operating margin.
XBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $725.3K | -29% |
| Q2 2026 | $660.6K | +12% |
| Q1 2026 | $806.9K | +36% |
| Q4 2025 | $766.3K | +18% |
| Q3 2025 | $1M | +67% |
| Q2 2025 | $589.9K | -19% |
| Q1 2025 | $593.3K | +16% |
| Q4 2024 | $648.8K | -3.4% |
XBIO's revenue fell from its 2025 peak and has held roughly level since: $725,257 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -240% | -187 points |
| Q2 2026 | -147% | -24 points |
| Q1 2026 | -62% | +97 points |
| Q4 2025 | -81% | +88 points |
| Q3 2025 | -53% | +28 points |
| Q2 2025 | -123% | +61 points |
| Q1 2025 | -159% | +90 points |
| Q4 2024 | -169% | +18 points |
XBIO's operating margin was −240% last quarter, down 187 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over XBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
XBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$662.1K | -$3.9K |
| Q2 2026 | -$875.5K | -$491.7K |
| Q1 2026 | -$536.4K | +$465.5K |
| Q4 2025 | -$242.7K | +$431.3K |
| Q3 2025 | -$658.2K | -$199.2K |
| Q2 2025 | -$383.8K | +$141.3K |
| Q1 2025 | -$1M | +$157.5K |
| Q4 2024 | -$674K | +$119K |
XBIO has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over XBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
XBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +48.8K shares |
| 1 year | +52% | +801K shares |
| 3 years | +54% | +818K shares |
| 5 years | +168% | +1.5M shares |
| Available history | +276% | +1.7M shares |
XBIO has 2M diluted shares, up 52% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
XBIO Net Leverage
XBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
XBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 8.3 | Oversold |
XBIO's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XBIO PE vs Healthcare Sector
XBIO has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over XBIO on trend strength, trading above more of its moving averages.
XBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.01 | 17% below |
| 20 week MA | $2.74 | 39% below |
| 50 week MA | $2.72 | 39% below |
| 100 week MA | $3.06 | 46% below |
| 200 week MA | $3.54 | 53% below |
XBIO is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
XBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.3 | $21.9 | +53% |
| 2021 | $21.9 | $14.4 | -34% |
| 2022 | $14.4 | $3.10 | -78% |
| 2023 | $3.10 | $3.45 | +11% |
| 2024 | $3.45 | $4.11 | +19% |
| 2025 | $4.11 | $2.08 | -49% |
| 2026 YTD | $2.08 | $1.66 | -20% |
XBIO has the edge over NVO on returns for 2026, with the stronger performance.